vs

Side-by-side financial comparison of BXP, Inc. (BXP) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

DENTSPLY SIRONA Inc. is the larger business by last-quarter revenue ($961.0M vs $872.1M, roughly 1.1× BXP, Inc.). BXP, Inc. runs the higher net margin — 15.3% vs -15.2%, a 30.4% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs 0.8%). Over the past eight quarters, BXP, Inc.'s revenue compounded faster (1.3% CAGR vs 0.4%).

BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

BXP vs XRAY — Head-to-Head

Bigger by revenue
XRAY
XRAY
1.1× larger
XRAY
$961.0M
$872.1M
BXP
Growing faster (revenue YoY)
XRAY
XRAY
+5.4% gap
XRAY
6.2%
0.8%
BXP
Higher net margin
BXP
BXP
30.4% more per $
BXP
15.3%
-15.2%
XRAY
Faster 2-yr revenue CAGR
BXP
BXP
Annualised
BXP
1.3%
0.4%
XRAY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BXP
BXP
XRAY
XRAY
Revenue
$872.1M
$961.0M
Net Profit
$133.0M
$-146.0M
Gross Margin
46.1%
Operating Margin
-14.5%
Net Margin
15.3%
-15.2%
Revenue YoY
0.8%
6.2%
Net Profit YoY
53.0%
66.0%
EPS (diluted)
$1.69
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BXP
BXP
XRAY
XRAY
Q1 26
$872.1M
Q4 25
$877.1M
$961.0M
Q3 25
$871.5M
$904.0M
Q2 25
$868.5M
$936.0M
Q1 25
$865.2M
$879.0M
Q4 24
$858.6M
$905.0M
Q3 24
$859.2M
$951.0M
Q2 24
$850.5M
$984.0M
Net Profit
BXP
BXP
XRAY
XRAY
Q1 26
$133.0M
Q4 25
$248.4M
$-146.0M
Q3 25
$-121.7M
$-427.0M
Q2 25
$89.0M
$-45.0M
Q1 25
$61.2M
$20.0M
Q4 24
$-228.9M
$-430.0M
Q3 24
$83.6M
$-494.0M
Q2 24
$79.6M
$-4.0M
Gross Margin
BXP
BXP
XRAY
XRAY
Q1 26
Q4 25
58.8%
46.1%
Q3 25
59.3%
48.8%
Q2 25
59.2%
52.4%
Q1 25
59.2%
53.0%
Q4 24
59.7%
49.3%
Q3 24
59.5%
52.1%
Q2 24
59.8%
51.9%
Operating Margin
BXP
BXP
XRAY
XRAY
Q1 26
Q4 25
-14.5%
Q3 25
-24.1%
Q2 25
-13.7%
Q1 25
7.2%
Q4 24
-56.2%
Q3 24
-48.6%
Q2 24
5.1%
Net Margin
BXP
BXP
XRAY
XRAY
Q1 26
15.3%
Q4 25
28.3%
-15.2%
Q3 25
-14.0%
-47.2%
Q2 25
10.2%
-4.8%
Q1 25
7.1%
2.3%
Q4 24
-26.7%
-47.5%
Q3 24
9.7%
-51.9%
Q2 24
9.4%
-0.4%
EPS (diluted)
BXP
BXP
XRAY
XRAY
Q1 26
$1.69
Q4 25
$1.56
$-0.74
Q3 25
$-0.77
$-2.14
Q2 25
$0.56
$-0.22
Q1 25
$0.39
$0.10
Q4 24
$-1.46
$-2.09
Q3 24
$0.53
$-2.46
Q2 24
$0.51
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BXP
BXP
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$512.8M
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$7.7B
$1.3B
Total Assets
$25.1B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BXP
BXP
XRAY
XRAY
Q1 26
$512.8M
Q4 25
$1.5B
$326.0M
Q3 25
$861.1M
$363.0M
Q2 25
$447.0M
$359.0M
Q1 25
$398.1M
$398.0M
Q4 24
$1.3B
$272.0M
Q3 24
$1.4B
$296.0M
Q2 24
$685.4M
$279.0M
Total Debt
BXP
BXP
XRAY
XRAY
Q1 26
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
Stockholders' Equity
BXP
BXP
XRAY
XRAY
Q1 26
$7.7B
Q4 25
$5.1B
$1.3B
Q3 25
$5.0B
$1.5B
Q2 25
$5.3B
$2.0B
Q1 25
$5.3B
$2.0B
Q4 24
$5.4B
$1.9B
Q3 24
$5.8B
$2.5B
Q2 24
$5.8B
$3.1B
Total Assets
BXP
BXP
XRAY
XRAY
Q1 26
$25.1B
Q4 25
$26.2B
$5.4B
Q3 25
$26.0B
$5.7B
Q2 25
$25.6B
$6.1B
Q1 25
$25.4B
$6.0B
Q4 24
$26.1B
$5.8B
Q3 24
$26.4B
$6.6B
Q2 24
$25.5B
$6.9B
Debt / Equity
BXP
BXP
XRAY
XRAY
Q1 26
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BXP
BXP
XRAY
XRAY
Operating Cash FlowLast quarter
$101.0M
Free Cash FlowOCF − Capex
$60.0M
FCF MarginFCF / Revenue
6.2%
Capex IntensityCapex / Revenue
1.5%
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BXP
BXP
XRAY
XRAY
Q1 26
Q4 25
$407.8M
$101.0M
Q3 25
$274.2M
$79.0M
Q2 25
$353.1M
$48.0M
Q1 25
$210.0M
$7.0M
Q4 24
$383.7M
$87.0M
Q3 24
$286.1M
$141.0M
Q2 24
$367.1M
$208.0M
Free Cash Flow
BXP
BXP
XRAY
XRAY
Q1 26
Q4 25
$362.7M
$60.0M
Q3 25
$231.6M
$40.0M
Q2 25
$281.5M
$16.0M
Q1 25
$152.6M
$-12.0M
Q4 24
$312.5M
$36.0M
Q3 24
$234.5M
$98.0M
Q2 24
$332.4M
$156.0M
FCF Margin
BXP
BXP
XRAY
XRAY
Q1 26
Q4 25
41.4%
6.2%
Q3 25
26.6%
4.4%
Q2 25
32.4%
1.7%
Q1 25
17.6%
-1.4%
Q4 24
36.4%
4.0%
Q3 24
27.3%
10.3%
Q2 24
39.1%
15.9%
Capex Intensity
BXP
BXP
XRAY
XRAY
Q1 26
1.5%
Q4 25
5.1%
4.3%
Q3 25
4.9%
4.3%
Q2 25
8.2%
3.4%
Q1 25
6.6%
2.2%
Q4 24
8.3%
5.6%
Q3 24
6.0%
4.5%
Q2 24
4.1%
5.3%
Cash Conversion
BXP
BXP
XRAY
XRAY
Q1 26
Q4 25
1.64×
Q3 25
Q2 25
3.97×
Q1 25
3.43×
0.35×
Q4 24
Q3 24
3.42×
Q2 24
4.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BXP
BXP

Lease$818.2M94%
Parking and other$30.8M4%
Development and management services$9.2M1%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons